Last updated: July 27, 2026
ecutive summary
Genzyme Corporation v. Teva Pharmaceuticals USA Inc., No. 1:13-cv-01508 (D. Mass.) is a federal patent infringement action in which Genzyme accused Teva of infringing Genzyme-held patents covering a Genzyme drug product. The case posture, asserted patent numbers, and adjudicative outcomes are not contained in the information provided here, so a litigation-summary and patent-estate analysis cannot be completed accurately.
1:13-cv-01508 Genzyme v. Teva infringement case: what happened procedurally?
No case caption record, docket events, claim construction orders, summary judgment rulings, trial outcomes, or appellate dispositions are available in the provided information. Without those docket facts, the procedural “what happened” narrative cannot be stated without risk of error.
What procedural milestones typically drive a patent-litigation summary for this docket
- Complaint filing and asserted patents
- Claim construction schedule and Markman order
- Motions to dismiss, for summary judgment, or to strike
- Trial and final judgment
- Stipulated dismissal, settlement, or consent judgment
- Appeal to the First Circuit or other appellate activity
Which patents did Genzyme assert in 1:13-cv-01508?
Asserted patent numbers and their titles are required to provide a defensible litigation analysis. The provided input does not include the asserted patents, independent claims, or infringement theories (product-by-process vs. composition, formulation vs. method-of-use, etc.), so the “which patents” section cannot be produced.
Claim-scope dimensions that determine infringement risk
- Composition claims vs. method-of-use claims
- Composition claims tied to specific active ingredient forms
- Formulation claims tied to excipients and ratios
- Manufacturing/process claims tied to steps and parameters
- Priority dates and claim construction outcomes
How did the court construe key claims in Genzyme v. Teva (1:13-cv-01508)?
Claim construction outcomes (terms construed, indefiniteness findings, limitations added or narrowed) are core to any analysis of strength and design-around feasibility. No claim construction or order text is included here.
Why claim construction usually changes the settlement and launch calculus
- Narrowing can invalidate infringement arguments for a competitor’s generic or biosimilar product
- Broadening can increase risk exposure and accelerate settlement timelines
- Consistent claim construction affects future related litigations and licensing leverage
Did Genzyme win, lose, or settle in 1:13-cv-01508?
Final disposition requires docket confirmation: final judgment, JMOL/compromise, or settlement with terms. The provided information includes only the case name/number and parties, which is insufficient to state an accurate litigation outcome.
Outcomes that materially affect patent-expiration and generic entry planning
- Court judgment on infringement and validity
- Settlement with “launch at risk” vs. “no-launch” terms
- Covenant not to sue or dismissal after licensing
- Entry-triggered payments or royalties
- Stipulated dismissal tied to a specified milestone
What Paragraph IV or FDA pathway issues relate to this litigation?
Genzyme-vs-Teva patent suits commonly track Hatch-Waxman Paragraph IV certifications and FDA Orange Book listings. The input does not identify:
- the drug and NDA/ANDA numbers
- the Orange Book patents at issue
- the certification type and filing date
- whether the suit is tied to the 30-month stay
Without those anchor facts, an FDA pathway analysis cannot be completed.
Orange Book and FDA filings that typically drive the lawsuit narrative
- NDA/ANDA identifiers
- Listed patents (drug substance, drug product, method-of-use)
- Certification letters (I, II, III, IV)
- 30-month stay end date
- Approval and launch dates
What does the litigation imply for Teva’s generic entry risk?
A generic-launch risk assessment requires:
- whether infringement and validity were found
- which patents remained in force after rulings
- whether Teva settled and what date triggers applied
- whether an injunction issued or was stayed
None of those items are available in the provided content.
How strong is Genzyme’s patent estate behind this case?
Patent-estate strength is normally evaluated using:
- remaining term(s) and expiration dates
- claim breadth post-construction
- validity outcomes for each asserted patent
- family size and continuation coverage
- secondary patents (formulation, manufacturing, method-of-use)
The asserted patent numbers, family details, and outcomes are not provided, so the strength analysis cannot be produced.
What generic/market competition scenarios follow from this litigation?
A realistic launch scenario depends on:
- whether Teva obtained an approval
- whether a “design-around” product was permitted
- whether future appeals changed enforceability
- what patents were carved out in settlement or dismissal
No product identifiers, FDA posture, or settlement terms are provided here.
Key Takeaways
- No procedurally grounded litigation summary or patent-estate analysis can be completed for Genzyme Corporation v. Teva Pharmaceuticals USA Inc., 1:13-cv-01508, because asserted patents, docket events, claim construction, and case disposition are not included in the provided information.
- No FDA/Orange Book tie-in analysis can be performed without the drug identifier, NDA/ANDA numbers, certification basis, and listed patents.
FAQs
- What patents were asserted in Genzyme v. Teva (1:13-cv-01508)?
- What claim-construction rulings affected infringement analysis in 1:13-cv-01508?
- Was the case resolved by judgment or settlement, and what were the triggers for generic entry?
- Which FDA application (NDA/ANDA) and Orange Book patents were linked to 1:13-cv-01508?
- How did the court treat validity defenses (anticipation, obviousness, §101, indefiniteness) in 1:13-cv-01508?
References
- (No sources were provided in the prompt to cite.)
